*Załącznik nr 1*

*do Specyfikacji Warunków Zamówienia*

*nr TP-....../25*

*Załącznik nr 1*

*do umowy nr TP-…../25*

**SZCZEGÓŁOWA WYCENA I OPIS PRZEDMIOTU ZAMÓWIENIA**

* 1. **Odczynniki do oznaczeń immunohistochemicznych i hybrydyzacji in situ (ISH)**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Lp** | **przeciwciało** | **numer katalogowy** | **ilość testów na 2 lata** | **klon** | **ilość testów w 1 op.** | **cena op. netto** | **ilość op.** | **wartość netto** | **vat****%** | **wartość brutto** |
| 1 | CD15 |  | 55 | (MMA) |  |  |  |  |  |  |
| 2 | PSA |  | 55 | (polyclonal) |  |  |  |  |  |  |
| 3 | CD43 |  | 55 | (L60) |  |  |  |  |  |  |
| 4 | Desmina |  | 55 | (DE-R-11) |  |  |  |  |  |  |
| 5 | Chromogranina A |  | 160 | (LK2H10) |  |  |  |  |  |  |
| 6 | S-100 |  | 380 | (polyclonal) |  |  |  |  |  |  |
| 7 | CD20 |  | 280 | (L26) |  |  |  |  |  |  |
| 8 | Cytokeratyna (Pan) |  | 1200 | (AE1/AE3 & PCK26) |  |  |  |  |  |  |
| 9 | Alfa-fetoproteina (AFP) |  | 55 | (polyclonal) |  |  |  |  |  |  |
| 10 | Aktyna Smooth Muscle (SMA) |  | 170 | (1A4) |  |  |  |  |  |  |
| 11 | bcl-6 |  | 60 | (GI191E/A8) |  |  |  |  |  |  |
| 12 | CD21 |  | 55 | (2G9) |  |  |  |  |  |  |
| 13 | CD138 |  | 55 | (B-A38) |  |  |  |  |  |  |
| 14 | EMA |  | 80 | (E29) |  |  |  |  |  |  |
| 15 | CD45 (LCA) |  | 90 | (2B11 & PD7/26) |  |  |  |  |  |  |
| 16 | Cytokeratyna 19 |  | 85 | (A53-B/A2.26) |  |  |  |  |  |  |
| 17 | HSA |  | 55 | (OCH1E5) |  |  |  |  |  |  |
| 18 | Progesteron  |  | 1600 | (1E2) |  |  |  |  |  |  |
| 19 | Vimentyna |  | 95 | (V9) |  |  |  |  |  |  |
| 20 | CD30 |  | 110 | (Ber-H2) |  |  |  |  |  |  |
| 21 | CD34 |  | 160 | (QBEnd/10) |  |  |  |  |  |  |
| 22 | CD68 |  | 270 | (KP-1) |  |  |  |  |  |  |
| 23 | CD117 C-kit |  | 160 | (9.7) |  |  |  |  |  |  |
| 24 | Melan A |  | 390 | (A103) |  |  |  |  |  |  |
| 25 | Ki-67 |  | 2600 | (30-9) |  |  |  |  |  |  |
| 26 | Estrogen  |  | 2400 | (SP1) |  |  |  |  |  |  |
| 27 | CD3 |  | 180 | (2GV6) |  |  |  |  |  |  |
| 28 | CD31 |  | 170 | (JC70) |  |  |  |  |  |  |
| 29 | CD23 |  | 55 | (SP23) |  |  |  |  |  |  |
| 30 | Cytokeratyna HMW |  | 60 | (34betaE12) |  |  |  |  |  |  |
| 31 | Melanosome (HMB45) |  | 580 | (HMB45) |  |  |  |  |  |  |
| 32 | PAX-5 |  | 55 | (SP34) |  |  |  |  |  |  |
| 33 | Cytokeratyna 20 |  | 280 | (SP33) |  |  |  |  |  |  |
| 34 | CD10  |  | 190 | (SP67) |  |  |  |  |  |  |
| 35 | Cyklina D1 |  | 55 | (SP4-R) |  |  |  |  |  |  |
| 36 | p63 |  | 2000 | (4A4) |  |  |  |  |  |  |
| 37 | E-kadheryna |  | 1000 | (36) |  |  |  |  |  |  |
| 38 | CD5 |  | 55 | (SP19) |  |  |  |  |  |  |
| 39 | Cytokeratyna 7 |  | 480 | (SP52) |  |  |  |  |  |  |
| 40 | bcl-2 |  | 180 | (124) |  |  |  |  |  |  |
| 41 | Cytokeratyna 5&6 |  | 480 | (D5/16B4) |  |  |  |  |  |  |
| 42 | MUM1 |  | 155 | (MRQ-43) |  |  |  |  |  |  |
| 43 | Synaptofizyna |  | 170 | (MRQ-40) |  |  |  |  |  |  |
| 44 | MSH2 |  | 60 | G219-1129 |  |  |  |  |  |  |
| 45 | Glypikan 3 |  | 60 | 1G12 |  |  |  |  |  |  |
| 46 | Kalretynina |  | 55 | SP65 |  |  |  |  |  |  |
| 47 | MLH-1 |  | 60 | M1 |  |  |  |  |  |  |
| 48 | TTF-1 |  | 190 | (SP141) |  |  |  |  |  |  |
| 49 | P53 |  | 390 | BP-53-11 |  |  |  |  |  |  |
| 50 | ALK 1 |  | 55 | ALK01 |  |  |  |  |  |  |
| 51 | AR |  | 55 | SP107 |  |  |  |  |  |  |
| 52 | Glutamine Synthetase |  | 55 | GS-6 |  |  |  |  |  |  |
| 53 | *Beta-Catenin* |  | 55 | 14 |  |  |  |  |  |  |
| 54 | CD56 |  | 180 | MRQ-42 |  |  |  |  |  |  |
| 55 | *caldesmon* |  | 55 | E89 |  |  |  |  |  |  |
| 56 | CD99 |  | 55 | 013 |  |  |  |  |  |  |
| 57 | CDX-2 |  | 180 | EPR2764Y |  |  |  |  |  |  |
| 58 | GCDFP15 |  | 55 | EP1582Y |  |  |  |  |  |  |
| 59 | kalcytonina |  | 55 | SP17 |  |  |  |  |  |  |
| 60 | mammoglobina |  | 55 | 31A5 |  |  |  |  |  |  |
| 61 | *CEA* |  | 55 | *CEA* |  |  |  |  |  |  |
| 62 | MSH6 |  | 60 | 44 |  |  |  |  |  |  |
| 63 | MUC1 |  | 60 | H23 |  |  |  |  |  |  |
| 64 | MUC2 |  | 60 | MRQ-18 |  |  |  |  |  |  |
| 65 | MUC5AC |  | 60 | MRQ-19 |  |  |  |  |  |  |
| 66 | MUC6 |  | 60 | MRQ-20 |  |  |  |  |  |  |
| 67 | PMS2 |  | 60 | EPR3947 |  |  |  |  |  |  |
| 68 | VILLIN |  | 55 | CWWB1 |  |  |  |  |  |  |
| 69 | P16 |  | 480 | E6H4 |  |  |  |  |  |  |
| 70 | *DOG-1* |  | 55 | SP31 |  |  |  |  |  |  |
| 71 | *PAX8* |  | 190 | MRQ-50 |  |  |  |  |  |  |
| 72 | *INI-1* |  | 70 | MRQ-27 |  |  |  |  |  |  |
| 73 | *EpCam* |  | 55 | Ber-EP4 |  |  |  |  |  |  |
| 74 | *Gata3* |  | 180 | L5--823 |  |  |  |  |  |  |
| 75 | *RCC* |  | 55 | PN-15 |  |  |  |  |  |  |
| 76 | *IgG4* |  | 55 | MRQ-44 |  |  |  |  |  |  |
| 77 | *WT-1* |  | 70 | GF-H2 |  |  |  |  |  |  |
| 78 | *HBME-1* |  | 70 | - |  |  |  |  |  |  |
| 79 | *P40* |  | 70 | BC28 |  |  |  |  |  |  |
| 80 | *HER-2* |  | 1800 | 4B5 |  |  |  |  |  |  |
| 81 | *HHV-8* |  | 55 | 13B10 |  |  |  |  |  |  |
| 82 | *IgG* |  | 55 | - |  |  |  |  |  |  |
| 83 | *Inhibin* |  | 55 | R1 |  |  |  |  |  |  |
| 84 | *myogenin* |  | 55 | F5D |  |  |  |  |  |  |
| 85 | *NapsinA* |  | 55 | MRQ-60 |  |  |  |  |  |  |
| 86 | *PLAP* |  | 55 | NB10 |  |  |  |  |  |  |
| 87 | *PTH* |  | 55 | MRQ-31 |  |  |  |  |  |  |
| 88 | *S> M. Myosin* |  | 55 | SMMS-1 |  |  |  |  |  |  |
| 89 | *SOX-10* |  | 55 | SP267 |  |  |  |  |  |  |
| 90 | *Thyreoglobulin* |  | 55 | 2H11+GE1 |  |  |  |  |  |  |
| 91 | *AMACR* |  | 55 | SP116 |  |  |  |  |  |  |
| 92 | *PRAME* |  | 390 | EPR20330 |  |  |  |  |  |  |
| 93 | *TFE-3* |  | 60 | MRQ-37 |  |  |  |  |  |  |
| 94 | *P120* |  | 60 | 98 |  |  |  |  |  |  |
| 95 | Kappa |  | 55 | - |  |  |  |  |  |  |
| 96 | Lambda |  | 55 | - |  |  |  |  |  |  |
| 97 | Pax-2 |  | 55 | EP235 |  |  |  |  |  |  |
| 98 | HCG |  | 55 | - |  |  |  |  |  |  |
| 99 | MDM-2 |  | 55 | SMP14 |  |  |  |  |  |  |
| 100 | STAT6 |  | 55 | EP325 |  |  |  |  |  |  |
| 101 | MUC4 |  | 55 | 8G7 |  |  |  |  |  |  |
| 102 | TdT |  | 55 | TdT |  |  |  |  |  |  |
| 103 | MPO |  | 55 | Myeloperoxidase |  |  |  |  |  |  |
| 104 | CMV Blend |  | 55 | 8B1.2,1G5.2&2D4.2 |  |  |  |  |  |  |
| 105 | SALL4 |  | 55 | 6E3 |  |  |  |  |  |  |
| 106 | OCT-4 |  | 55 | MRQ-10 |  |  |  |  |  |  |
| 107 | szkiełka |  | 24000 |  |  |  |  |  |  |  |
| 108 | inne niezbędne odczynniki do automatycznego wykonania powyższych oznaczeń (w tym multimerowy system detekcyjny) oraz 1000 barwień podwójnychpodać rodzaje i ilość dla podanych powyżej przeciwciał: |  | 24000 |  |  |  |  |  |  |  |
| 109 | zestaw do wykonywania podwójnej Hybrydyzacji In Situ metodą SISH/CISH w kierunku HER-2/chromosom 17WYKONAWCA określa odczynniki, materiały kontrolne, kalibratory i materiały eksploatacyjne w ilości zapewniającej wykonanie wyżej wymienionych badań w okresie dzierżawy. WYKONAWCA informację o odczynnikach, materiałach kontrolnych, kalibratorach i materiałach eksploatacyjnych przekazuje z wyszczególnieniem wszystkich typów i rodzajów produktów, które ZAMAWIAJĄCY będzie nabywał od wykonawcy z precyzyjną informacją o cenach jednostkowych produktów, ich nazwach oraz numerach katalogowych. |  | 260 |  |  |  |  |  |  |  |
| 110 | kody kreskowe |  | 24000 |  |  |  |  |  |  |  |
| 111 | taśma do drukarki |  | 8 |  |  |  |  |  |  |  |
| **RAZEM:** |  | **X** |  |

* 1. **Dzierżawa dwóch aparatów do barwień IHC I ISH**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|   | **przedmiot dzierżawy** | **okres dzierżawy** | **kwota czynszu** **za 1 miesiąc netto** | **wartość czynszu** **w okresie 24 miesięcy netto** | **vat****%** | **wartość czynszu****w okresie 24 miesięcy brutto** |
| 1 | Dzierżawa dwóch aparatów do barwień IHC i ISH | 24 miesiące |   |   |   |  |
| **RAZEM** |  |  |  |

**Łączna wartość oferty** (suma wartości odczynników - Tab. 1 oraz czynszu - Tab. 2):

wartość netto - .................................. .zł wartość brutto - ....................................zł.